I might be getting ahead of myself, but would be keen to heat other people's take on this! Page 7 of the quarterly report (announcement 16th Nov), under the Liquidity section says "Should the company enter into commercial relationships relating to the industrialization, commercial supply or preferred use of a device within a particular therapeutic market, the Company may pursue additional funding or revenue streams... through the sale of additional equity or debt securities.".
UNS Price at posting:
95.5¢ Sentiment: Buy Disclosure: Held